The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Ken Takeshita, global head, R&D, Daiichi Sankyo, said: “Enhertu continues to transform the treatment of metastatic breast cancer with the first new data in more than a decade to demonstrate improved ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

CHICAGO — The cancer drug Enhertu stalled the growth of tumors ... reported Monday that the drug’s makers AstraZeneca and Daiichi Sankyo believe could change the way the disease is treated ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

1,2 ENHERTU (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate. Designed using Daiichi Sankyo's proprietary DXd antibody drug conjugate (ADC) technology, ENHERTU consists of a ...

TOKYO & BASKING RIDGE, N.J. - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) announced positive results from the phase 3 DESTINY-Breast09 trial, indicating that their drug ENHERTU®, ...